News & Events

Results of Operations and Financial Condition. On April 23, 2026, the Registrant announced its financial results for the fiscal quarter ended March 28, 2026. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Form 8-K and incorporated herein by reference. The information contained in this report and exhibits hereto shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act") o…

Other Events. On March 24, 2026, Thermo Fisher Scientific Inc. (“Thermo Fisher”) issued a press release announcing the completion of its acquisition of Clario Holdings, Inc. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

Other Events. The sale of the Notes was made pursuant to the terms of an Underwriting Agreement, which the Company entered into on February 9, 2026 (the “Underwriting Agreement”), with Deutsche Bank Securities Inc., RBC Capital Markets, LLC, SMBC Nikko Securities America, Inc. and Wells Fargo Securities, LLC, as representatives of the several underwriters named in Schedule A to the Underwriting Agreement. The Company expects that the net proceeds from the sale of the Notes will be approximate…

Entry into a Material Definitive Agreement. On February 12, 2026, Thermo Fisher Scientific Inc. (the “Company”) issued $1,000,000,000 aggregate principal amount of 4.215% Senior Notes due 2031 (the “2031 Notes”), $750,000,000 aggregate principal amount of 4.550% Senior Notes due 2033 (the “2033 Notes”), $1,300,000,000 aggregate principal amount of 4.902% Senior Notes due 2036 (the “2036 Notes”) and $750,000,000 aggregate principal amount of 5.546% Senior Notes due 2046 (the “2046 Notes” and,…

Results of Operations and Financial Condition. On January 29, 2026, the Registrant announced its financial results for the fiscal quarter and year ended December 31, 2025. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Form 8-K and incorporated herein by reference. The information contained in this report and exhibits hereto shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Ex…

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Each of Michel Lagarde and Frederick M. Lowery have notified Thermo Fisher Scientific Inc. (the “Company”) of their decisions to leave the Company to pursue other opportunities. Mr. Lagarde, who has served as Executive Vice President and Chief Operating Officer of the Company since 2021 will depart on March 31, 2026, and Mr. Lowery, who has served…

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On July 23, 2025, Thermo Fisher Scientific Inc. (the “Company”), announced that Stephen Williamson, Senior Vice President and Chief Financial Officer (CFO) will retire effective March 31, 2026. The Company also announced that the Board of Directors approved the appointment of James R. Meyer, 46, currently Vice President, Financial Operations of the…

Other Events On February 25, 2025, Thermo Fisher Scientific Inc. (“Thermo Fisher”) and Solventum Corporation (“Solventum”) entered into an agreement, pursuant to which, subject to the satisfaction or waiver of specified conditions, Thermo Fisher agreed to acquire Solventum’s purification and filtration business for approximately $4.1 billion in cash. The transaction is expected to be completed by the end of 2025 and is subject to customary closing conditions and regulatory approvals. Forward-…

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers On February 19, 2025, the Board of Directors (the “Board”) of Thermo Fisher Scientific Inc. (the “Company”) increased its size to twelve members and elected Karen S. Lynch as a director of the Company, effective February 19, 2025, for a term expiring at the Company’s 2025 annual meeting. The Board anticipates that Ms. Lynch will serve on the Audit C…

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers On July 13, 2023, Thermo Fisher Scientific Inc. (the “Company”) filed a Current Report on Form 8-K to announce the election of Jennifer “Jenny” Johnson as a director of the Company. At the time of such filing, the Board of Directors had not yet determined committee assignments for Ms. Johnson. On September 21, 2023, the Board of Directors appointed…

Regulation FD Disclosure. On August 8, 2023, Thermo Fisher Scientific Inc. (the “Company”) notified the holders of its (i) $500,000,000 aggregate principal amount of Floating Rate Senior Notes due 2023 (the “2023 Notes”) and (ii) $500,000,000 aggregate principal amount of Floating Rate Senior Notes due 2024 (the “2024 Notes” and, together with the 2023 Notes, the “Notes”) that it will redeem all of the Notes on August 18, 2023 (the “Redemption Date”). The 2023 Notes will be redeemed at a rede…

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers On July 13, 2023, the Board of Directors (the “Board”) of Thermo Fisher Scientific Inc. (the “Company”) increased its size to twelve members and elected Jennifer “Jenny” Johnson, president and chief executive officer of Franklin Resources, Inc., as a director of the Company, effective July 13, 2023, for a term expiring at the Company’s 2024 annual m…

of this Current Report on Form 8-K shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing. Cautionary Statement Regarding Forward-Looking Statements This Current Report o…

Regulation FD Disclosure. On December 15, 2021, Thermo Fisher Scientific Inc. (the “Company”) notified the holders of its (i) $1,200,000,000 aggregate principal amount of 2.950% Senior Notes due 2026 (the “2026 Notes”) and (ii) $750,000,000 aggregate principal amount of 3.200% Senior Notes due 2027 (the “2027 Notes” and, together with the 2026 Notes, the “Notes”) that it will redeem all of the Notes on December 30, 2021 (the “Redemption Date”). The 2026 Notes will be redeemed at a redemption…

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On September 23, 2021, Mark Stevenson, Executive Vice President and Chief Operating Officer of Thermo Fisher Scientific Inc. (the “Company”), notified the Company of his decision to retire effective March 18, 2022, and Syed Jafry, Senior Vice President, Regions, notified the Company of his decision to retire effective March 31, 2022. Also on Septem…

of this Form 8-K shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing. Cautionary Statement Regarding Forward-Looking Statements This Current Report on Form 8-K and today’s presentations conta…